Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1
CPT4 code
Name of the Procedure:
Infectious Agent Antigen Detection by Immunoassay Technique (e.g., Enzyme Immunoassay [EIA], Enzyme-Linked Immunosorbent Assay [ELISA], Immunochemiluminometric Assay [IMCA]) - Qualitative or Semiquantitative, Multiple-Step Method; HIV-1
Summary
This procedure detects the presence of specific antigens from infectious agents, particularly HIV-1, using immunoassay techniques. These techniques include enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), and immunochemiluminometric assay (IMCA). The test results can be either qualitative (positive/negative) or semiquantitative (low/medium/high).
Purpose
The procedure aims to diagnose HIV-1 infection by detecting the presence of HIV-1 antigens in the blood. Early detection assists in timely treatment and management of the condition to improve patient outcomes and prevent transmission.
Indications
- Individuals with possible exposure to HIV-1.
- Patients presenting symptoms suggestive of HIV infection (e.g., fever, swollen lymph nodes, rash).
- Routine screening in high-risk populations (e.g., intravenous drug users, multiple sexual partners).
- Follow-up testing for individuals with inconclusive initial HIV screening results.
Preparation
- No special preparation or fasting is generally required.
- Patients should inform their healthcare provider of any current medications or underlying health conditions.
- Blood sample collection will be necessary.
Procedure Description
- A blood sample is drawn from the patient.
- The sample is processed in the laboratory where an immunoassay is performed.
- In the laboratory, the sample is exposed to antibodies that specifically bind to HIV-1 antigens.
- If HIV-1 antigens are present, the antibodies will bind, causing a measurable reaction (color change, light emission).
- The reaction intensity is measured to provide qualitative or semiquantitative results.
Tools and Equipment:
- Blood collection tubes and needles.
- Immunoassay kits (EIA, ELISA, or IMCA).
- Laboratory equipment for analysis (e.g., spectrophotometer, luminometer).
Duration
The entire process, from blood sample collection to result interpretation, typically takes a few hours to a few days, depending on the laboratory capacity and technology used.
Setting
This procedure is usually performed in a laboratory setting. Blood sample collection can take place in a hospital, outpatient clinic, or physician’s office.
Personnel
- Phlebotomist (for blood sample collection).
- Laboratory technician or technologist (for performing the immunoassay).
- Pathologist or medical laboratory scientist (for result validation).
Risks and Complications
- Minor discomfort or bruising at the blood draw site.
- Rare risks include infection or excessive bleeding at the puncture site.
Benefits
- Early and accurate detection of HIV-1 infection.
- Enables timely initiation of antiretroviral therapy (ART).
- Helps prevent the spread of HIV-1 to others.
Recovery
- Patients can resume normal activities immediately after the blood draw.
- Follow-up appointments may be scheduled to discuss results and subsequent steps.
Alternatives
- Rapid HIV tests (usually qualitative and provide results within 30 minutes).
- Polymerase Chain Reaction (PCR) tests for HIV RNA (more sensitive but also more expensive and time-consuming).
- Western Blot or Immunofluorescence assay (IFA) as confirmatory tests.
Patient Experience
- The patient may feel a quick pinch during blood sample collection and slight discomfort at the puncture site.
- No significant pain or downtime is expected.
- Results discussion might cause anxiety; appropriate counseling and support should be provided.